August 1, 2024 Advancing Rare Disease Measurement With The Rare Disease COA Resource It is estimated that more than 350 million people worldwide live with a rare disease.
April 24, 2024 COA Program Concludes Successful Annual Meeting On April 17 and 18, C-Path's Clinical Outcome Assessment (COA) Program hosted its Annual Meeting in Rockville, MD...
April 23, 2024 Clinical Outcome Assessment — Initial Public Discussion In this presentation from C-Path's rare and orphan disease program, you will see...
April 17, 2024-April 18, 2024 2024 Clinical Outcome Assessment Program Annual Meeting On April 17-18, 2024, the 2024 Clinical Outcome Assessment Annual Meeting...
April 10, 2024 Critical Path Institute Announces New Board Members Bonnie A. Allin and Louis Breton Critical Path Institute (C-Path) today announced the appointments of Bonnie A. Allin and Louis Breton to its Board of Directors.
February 7, 2024 Dr. Janet Woodcock: A Visionary Leader in Regulatory Science and the Inspirational Force behind the Creation of Critical Path Institute In her nearly four decades with the U.S. Food and Drug Administration, Dr. Janet Woodcock personally transformed the culture of...
January 25, 2024 C-Path Promotes Cécile Ollivier to Vice President of Global Affairs, Expanding Leadership in Drug Development Critical Path Institute (C-Path) today announced the promotion of Cécile Ollivier, M.S., from Managing Director, Europe to...
January 22, 2024 C-Path’s TRxA Announces its 2024 Global Request for Proposals from Academic Investigators Working to Advance Drug Development Projects Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced...
January 9, 2024 C-Path Appoints Dr. Klaus Romero as New CEO Longtime quantitative medicine and regulatory science expert to spearhead C-Path's collaborative efforts in accelerating...
December 8, 2023 Understanding the Role of Patient Data in Drug Development Panel within a session titled “Understanding the role of patient data in drug development” at the 2023 International...
